Glaukos Stock News & Updates
[WKN: A14VCK | Symbol: GKOS]
Glaukos – Epioxa sales nearly quintupled! 1 billion in revenue on the horizon for 2027
Epioxa makes cornea therapy gentler. Quarterly sales jump from 11 to 53 million USD. iDose TR releases...
Glaukos: Micro-Implants Instead of Eye Drops
Glaukos primarily earns its money from surgical single-use implants for micro-invasive glaucoma procedures,...
Glaukos: Specialist in Ophthalmology Grows by 50% Thanks to iDose TR Demand
Glaukos focuses on ophthalmology with tiny implants and therapies. The second quarter impresses...
Glaukos: Ophthalmology Specialist Sees Significant Gains After Forecast Upgrade!
Outstanding Q2 figures: An impressive revenue increase of +49.54% to $185.61 million far exceeds...
Glaukos: iDose Breakthrough Fuels Volume Rally after a Forecast Upgrade
The massive revenue jump in Q1 2026 of 41% confirms market acceptance of the iDose TR implant and...
Analysts' Top 5 Price Targets of March 24, 2026
Ottobock SE [DE000BCK2223] UBS upgrades from Neutral to Buy - Price target remains €74 (43% upside...
Glaukos - Rising Treatment Numbers Drive Momentum!
Business Drivers: Glaukos (GKOS) is a specialist in minimally invasive procedures and micro-implants...
Glaukos - Increasing treatment numbers significantly boost results!
Business driver: Glaukos (GKOS) specializes in minimally invasive techniques and micro-implants for...
Glaukos – New iDose Implant and Epioxa Procedure Should Significantly Boost Results for Eye Care Specialist!
Business Driver: Glaukos (GKOS) specializes in minimally invasive procedures and micro-implants for...
Analysts' Top 5 Price Targets of October 27, 2025
Fermi Inc. [US3149111086] Berenberg starts coverage with Buy and a price target of $37 (50% upside...
Analysts' Top 5 Price Targets of May 26, 2025
Glaukos Corp. [US3773221029]: Piper Sandler reaffirms Buy rating with a price target of $165 (70% upside...
- ‹
- 1
- ›